"Ensuring Stable Supply of Consumables"... JVM's Q1 Sales Rise 6.2% to 45.5 Billion Won

Record-High First-Quarter Sales Achieved

JVM, a global leader in the automated pharmaceutical dispensing sector, continued its solid performance in the first quarter of 2026, maintaining stable business operations despite domestic and international raw material supply uncertainties caused by the Middle East conflict.

JVM, an affiliate of Hanmi Science, announced on the 29th that its consolidated provisional results for the first quarter of this year included sales of 45.5 billion won, operating profit of 9.3 billion won, and net profit of 7.6 billion won.

Compared to the same period last year, sales increased by 6.2%, marking the highest first-quarter performance to date, while operating profit rose by 4.8%. By region, sales distribution was 47.9% domestic and 52.1% overseas (Europe 23.2%, North America 18.3%, and other regions 10.6%), maintaining a balanced portfolio between domestic and export markets. For future growth, JVM invested 2.2 billion won in R&D, which represents 4.8% of consolidated sales.

In the domestic market, concerns about raw material supply emerged due to geopolitical influences from the Middle East, leading to a temporary spike in demand for securing consumables. In response, the company, with active government support, made every effort to stabilize the supply of raw materials and promptly met domestic demand, minimizing any disruptions in domestic automated dispensing work.

At the same time, JVM is also enhancing its product competitiveness. The company is upgrading its product portfolio with next-generation, robot-based automated dispensing equipment such as MENITH and COUNTMATE. Notably, MENITH has completed an upgrade to enhance its inspection functions.

Meanwhile, Hanmi Pharmaceutical and Online Pharm are each responsible for JVM’s overseas and domestic operations, respectively, while JVM is focusing on R&D and production for next-generation new product development. Hanmi Group supplies JVM equipment to 60 countries worldwide through 35 global partners.

Sangwook Kim, CEO of JVM, stated, "Amid ongoing external uncertainties, we are closely managing the entire process from raw material procurement to production, maintaining a stable supply system," and added, "We will continue to do our utmost to ensure stable production and supply of equipment and consumables so that no disruptions occur at medical sites."

This content was produced with the assistance of AI translation services.